PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
231.81%
G&A growth while AGEN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
-559.42%
Other expenses reduction while AGEN shows 0.00% growth. Joel Greenblatt would examine efficiency.
182.89%
Operating expenses growth while AGEN reduces costs. John Neff would investigate differences.
182.89%
Total costs growth while AGEN reduces costs. John Neff would investigate differences.
10.64%
Interest expense growth while AGEN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
-245.34%
EBITDA decline while AGEN shows 21.65% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-249.64%
Operating income decline while AGEN shows 18.38% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56.01%
Both companies reducing tax expense. Martin Whitman would check patterns.
-146.74%
Net income decline while AGEN shows 117.52% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-145.19%
EPS decline while AGEN shows 116.22% growth. Joel Greenblatt would examine position.
-145.19%
Diluted EPS decline while AGEN shows 116.22% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.